Form 4: Spyre Therapeutics Director Sells Shares Under 10b5-1 Trading Plan

Jeffrey W. Albers, a director of Spyre Therapeutics, Inc., sold 300 shares of common stock at a price of $36.43 per share on October 25, 2024, according to a Form 4 filing with the SEC.

Summary

• On October 25, 2024, Jeffrey W. Albers, a director of Spyre Therapeutics, Inc. (SYRE), sold 300 shares of common stock.
• The sale was executed at a price of $36.43 per share.
• Following the transaction, Albers directly owns 34,060 shares and indirectly owns shares through Sessions LLC.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily reflect a change in the director's outlook on the company.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under pre-arranged 10b5-1 trading plans are less indicative of current sentiment as they are often established for personal financial planning reasons.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates